ALS Texas

How Your Donations Impact Local ALS Research

by Leave a Comment

The ALS Association funds the world’s largest ALS research program, working with more than 150 labs around the globe. The ALS Association supports a wide breadth of specific fields of study that are critical to advancing ALS research.

A significant portion of the research funded by the ALS Association is done through the vast network of clinical research and clinical trials. The ALS Association funds a nation-wide network of Certified Treatment Centers of Excellence, which must meet the ALS Association’s clinical care and treatment standards based on the American Academy of Neurology Practice Parameters. In order to achieve this certification, the clinic must participate in ALS-related research and successfully complete a comprehensive site review.

[Read more…]

New Gene Discovered that Contributes to ALS

by 1 Comment

$1 Million Grant from Ice Bucket Challenge Helped Spur Discovery

Today, researchers from Project MinE announced that they have identified a new gene NEK1 that ranks among the most common genes that contribute to ALS. The study revealed an association between mutations in the gene and ALS. The discovery of NEK1 gives scientists an exciting new target for drug development.

Approximately 10 percent of ALS cases are familial, meaning genes are inherited from a family member. The other 90 percent of ALS cases are sporadic, or without a family history. The NEK1 gene is present in approximately 3 percent of all ALS cases.

[Read more…]

Congress Takes Action on ALS Priorities

by Leave a Comment

Thanks to nationwide advocacy efforts, Congress is taking action on several priorities for the ALS Community.

The Senate Appropriations Committee passed the fiscal year 2017 Health and Human Services spending bill and included $10 million to continue funding to the National ALS Registry. The National ALS Registry is a congressionally directed registry for people in the U.S. with ALS. It is a program to collect, manage, and analyze data about people with living with ALS, which helps doctors and scientists learn more as they work toward a cure. It is the only population-based registry in the U.S.

[Read more…]

FDA Approval Sought for New ALS Drug

by 9 Comments

Pharmaceutical company Mitsubishi Tanabe Pharma Corporation submitted a formal proposal to the United States Food and Drug Administration for approval of a drug to treat ALS. The drug, Edaravone, gets rid of toxic waste that is a normal by-product of cell function. It is thought that this waste is not as effectively removed in ALS patients, causing damage to motor neurons, which are the cells that die in ALS patients. Edaravone would protect these neurons by helping rid the cells of this waste.

The Edaravone new drug application is supported by clinical research with ALS patients in Japan, and in 2015, Edaravone was approved as a treatment for ALS in Japan and South Korea. After being submitted to the FDA for consideration, it could either be automatically approved for use in the U.S., or it could require a Phase III study conducted in the U.S.

[Read more…]

Scientists Take Promising First Step in Accelerating ALS Diagnosis

by Leave a Comment

The Neurological Clinical Research Institute has recently made significant strides in working toward diagnosing ALS earlier and measuring the progression of the disease. The NCRI imaging team conducted its first successful PET imaging scan of a person living with ALS to measure inflammation in the brain, which is a promising first step in the TRACK ALS imaging biomarker study.

Dr. Nazem Atassi and his team at Massachusetts General Hospital developed a tracer that binds to support cells of the nervous system in the brain. The tracer serves as a marker of inflammation and tracks changes in the cells of the nervous system. The PET imaging scans measure inflammation in the central nervous system, where cells move to the already damaged area of the brain and worsen damage by further harming neurons.

[Read more…]

ALS BrainStorm Stem Cell Clinical Trials Update

by 3 Comments

JAMA Neurology has published a paper titled, “Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis – Results of Phase1/2 and 2a Clinical Trials.” This study comes out of a collaboration of researchers from BrainStorm Cell Therapeutics and the Hadassah-Hebrew University Medical Center both located in Israel.

The researchers set out to understand the safety and clinical effects of treatment with mesenchymal stem cells induced to secrete neurotrophic factors (MSC-NTF) in patients with ALS. Stem cells used in this study are adult mesenchymal stem cells derived from bone marrow samples given by participants in the trial. The bone marrow cells are turned into stem cells that secrete the NTFs. NTFs are a type of nutrient for cells and were previously shown to have protective effects in animal models of neurodegenerative disease.

[Read more…]

ALS Association Awards $1.3M to 9 New ALS Research Projects

by Leave a Comment

We are excited to announce funding for  nine new ALS research projects! The ALS Association awarded more than $1.3M to projects across the country, furthering investigation into the cause, treatments and cure for ALS.  Projects include research on the C9orf72 gene, which has been identified as the most common cause of familial ALS.  The research awards include ALS Association-Initiated Grants, Investigator-Initiated Biomarker Grants, and the Milton Safenowitz Postdoctoral Fellowships.

To learn more about these research grants and initiatives, visit alsa.org.